Global prevalence of ultra-short coeliac disease (USCD): the first systematic review and meta-analysis

IF 23 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gut Pub Date : 2025-03-20 DOI:10.1136/gutjnl-2024-334688

Sahand Karimzadhagh, Behrooz Ahmadi, Meysam Olfatifar, Hamidreza Houri, Nastaran Asri, Mohammad Rostami-Nejad, David S Sanders

{"title":"Global prevalence of ultra-short coeliac disease (USCD): the first systematic review and meta-analysis","authors":"Sahand Karimzadhagh, Behrooz Ahmadi, Meysam Olfatifar, Hamidreza Houri, Nastaran Asri, Mohammad Rostami-Nejad, David S Sanders","doi":"10.1136/gutjnl-2024-334688","DOIUrl":null,"url":null,"abstract":"We reviewed the recent cohort study by Raju et al 1 on ultra-short coeliac disease (USCD), the first multicentre international study assessing the characteristics of this new entity and comparing them to classic coeliac disease. The study revealed findings that may necessitate a re-evaluation of the current diagnostic guidelines and screening protocols. However, the results showed disparities in USCD prevalence rates among biopsy-confirmed cases across centres, ranging from 0.2% to 8.8%. Moreover, the study did not report the number of bulb biopsies conducted at each centre. Hence, we aimed to systematically assess the global prevalence of USCD and determine factors that might influence its rates. See the online supplemental document for subgroup analyses and methodology. Literature was searched from inception to June 2024 (PubMed, Web of Science, Cochrane, Scopus) for studies reporting the prevalence of USCD, using the term or reporting seropositive cases with villous atrophy (VA) confined to the bulb1 among biopsy-confirmed coeliac disease (CeD) participants.2 3 Meta-analyses were conducted using STATA V.18.0. Notably, two investigators independently performed each step, from screening to data extraction and quality assessment.### Supplementary data [gutjnl-2024-334688supp001.pdf] 32 …","PeriodicalId":12825,"journal":{"name":"Gut","volume":"33 1","pages":""},"PeriodicalIF":23.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/gutjnl-2024-334688","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We reviewed the recent cohort study by Raju et al 1 on ultra-short coeliac disease (USCD), the first multicentre international study assessing the characteristics of this new entity and comparing them to classic coeliac disease. The study revealed findings that may necessitate a re-evaluation of the current diagnostic guidelines and screening protocols. However, the results showed disparities in USCD prevalence rates among biopsy-confirmed cases across centres, ranging from 0.2% to 8.8%. Moreover, the study did not report the number of bulb biopsies conducted at each centre. Hence, we aimed to systematically assess the global prevalence of USCD and determine factors that might influence its rates. See the online supplemental document for subgroup analyses and methodology. Literature was searched from inception to June 2024 (PubMed, Web of Science, Cochrane, Scopus) for studies reporting the prevalence of USCD, using the term or reporting seropositive cases with villous atrophy (VA) confined to the bulb1 among biopsy-confirmed coeliac disease (CeD) participants.2 3 Meta-analyses were conducted using STATA V.18.0. Notably, two investigators independently performed each step, from screening to data extraction and quality assessment.### Supplementary data [gutjnl-2024-334688supp001.pdf] 32 …

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Gut 医学-胃肠肝病学

CiteScore

45.70

自引率

2.40%

发文量

284

审稿时长

1.5 months

期刊介绍： Gut is a renowned international journal specializing in gastroenterology and hepatology, known for its high-quality clinical research covering the alimentary tract, liver, biliary tree, and pancreas. It offers authoritative and current coverage across all aspects of gastroenterology and hepatology, featuring articles on emerging disease mechanisms and innovative diagnostic and therapeutic approaches authored by leading experts. As the flagship journal of BMJ's gastroenterology portfolio, Gut is accompanied by two companion journals: Frontline Gastroenterology, focusing on education and practice-oriented papers, and BMJ Open Gastroenterology for open access original research.